Clinical Trial

Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Consolidative immunotherapy following concurrent chemoradiotherapy, based on the PACIFIC trial, has become the standard treatment for locally advanced non-small cell lung cancer (LANSCLC). Radiotherapy strategies for maximizing efficacy and local control require further investigation. This phase III, randomized controlled clinical trial is to investigate the efficacy and safety of hypofractionated chemoradiotherapy followed by consolidative immunotherapy versus conventional fractionated chemoradiotherapy followed by consolidative immunotherapy in LANSCLC patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-30.
Trial Details
NCT Number NCT07052669
Lead Sponsor Sun Yat-sen University
Conditions Locally Advanced Non-Small Cell Lung Cancer
Enrollment 311 participants
Start Date 2025-07-01
Primary Completion 2029-06-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-23